To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Resource Library
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
ANEM Posters and Presentations 2024
AANEM 2024
Clinical Outcomes, Disease Course, and Quality of Life in Patients With MultifocalMotor Neuropathy iMMersioN, Study in Progress
January 1, 2024
Clinical Outcomes, Disease Course, and Quality of Life in Patients With MultifocalMotor Neuropathy iMMersioN, Study in Progress
January 1, 2024
Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
January 1, 2024
Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
January 1, 2024
Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
January 1, 2024
Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
January 1, 2024
Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
January 1, 2024
Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
January 1, 2024
COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
January 1, 2024
COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
January 1, 2024
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: ADHERE Trial Subgroup Analysis
January 1, 2024
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: ADHERE Trial Subgroup Analysis
January 1, 2024
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHEREADHERE+ Trials
January 1, 2024
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHEREADHERE+ Trials
January 1, 2024
Efficacy, Safety, and Pharmacodynamics of Efgartigimod PH20 SC Across Bodyweight Quartiles A Post hoc Analysis of the ADAPT-SC+ Trial
January 1, 2024
Efficacy, Safety, and Pharmacodynamics of Efgartigimod PH20 SC Across Bodyweight Quartiles A Post hoc Analysis of the ADAPT-SC+ Trial
January 1, 2024
Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy Initial Safety and Efficacy Data of the Phase 2 ARDA Study
January 1, 2024
Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy Initial Safety and Efficacy Data of the Phase 2 ARDA Study
January 1, 2024
Empasiprubart(ARGX-117) in Multifocal Motor Neuropathy Baseline Characteristics and MMN Confirmation Committee Outcomes of the Phase 2 ARDA Study
January 1, 2024
Empasiprubart(ARGX-117) in Multifocal Motor Neuropathy Baseline Characteristics and MMN Confirmation Committee Outcomes of the Phase 2 ARDA Study
January 1, 2024
Exploring the Impact of Nonsteroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients With Myasthenia Gravis
January 1, 2024
Exploring the Impact of Nonsteroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients With Myasthenia Gravis
January 1, 2024
Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
January 1, 2024
Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
January 1, 2024
Heterogeneity of EQ-5D-5L utilities among people suffering from CIDP
January 1, 2024
Heterogeneity of EQ-5D-5L utilities among people suffering from CIDP
January 1, 2024
Long-Term Safety and Efficacy of Efgartigimod PH20 SC in Generalized Myasthenia Gravis: Interim Analysis of Anti-Acetylcholine Receptor Antibody Seronegative Participants in ADAPT-SC+
January 1, 2024
Long-Term Safety and Efficacy of Efgartigimod PH20 SC in Generalized Myasthenia Gravis: Interim Analysis of Anti-Acetylcholine Receptor Antibody Seronegative Participants in ADAPT-SC+
January 1, 2024
Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
January 1, 2024
Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
January 1, 2024
Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
January 1, 2024
Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
January 1, 2024
Patterns Of Efgartigimod Dosing In Clinical Practice In The United States
January 1, 2024
Patterns Of Efgartigimod Dosing In Clinical Practice In The United States
January 1, 2024
Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
January 1, 2024
Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
January 1, 2024
Quality Of Life of Patients with Symptomatic Ocular MG Comparison with the General Population
January 1, 2024
Quality Of Life of Patients with Symptomatic Ocular MG Comparison with the General Population
January 1, 2024
Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
January 1, 2024
Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
January 1, 2024
Risk of Serious Infections and Malignancies in Adult Myasthenia Gravis Patients A US Claims Database Study
January 1, 2024
Risk of Serious Infections and Malignancies in Adult Myasthenia Gravis Patients A US Claims Database Study
January 1, 2024
Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
January 1, 2024
Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
January 1, 2024
Safety Profile of Subcutaneous Efgartigimod PH20 From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
January 1, 2024
Safety Profile of Subcutaneous Efgartigimod PH20 From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
January 1, 2024
Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients With Amyotrophic Lateral Sclerosis A Phase 2a Study in Progress
January 1, 2024
Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients With Amyotrophic Lateral Sclerosis A Phase 2a Study in Progress
January 1, 2024
Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes: Phase 1b Study in Progress
January 1, 2024
Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes: Phase 1b Study in Progress
January 1, 2024
Steroid Toxicity in Adults With Myasthenia Gravis in the United States Based on Electronic Health Records
January 1, 2024
Steroid Toxicity in Adults With Myasthenia Gravis in the United States Based on Electronic Health Records
January 1, 2024
Steroid Use, Toxicity, and Monitoring in Patients With Chronic Inflammatory Demyelinating Polyneuropathy A Survey of Neurologists in the United States
January 1, 2024
Steroid Use, Toxicity, and Monitoring in Patients With Chronic Inflammatory Demyelinating Polyneuropathy A Survey of Neurologists in the United States
January 1, 2024
Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States
January 1, 2024
Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States
January 1, 2024
Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy Key Secondary Outcomes From the ADHERE Trial
January 1, 2024
Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy Key Secondary Outcomes From the ADHERE Trial
January 1, 2024
The Burden people suffering from CIDP experience In terms of Utilities Comparison With The General Population
January 1, 2024
The Burden people suffering from CIDP experience In terms of Utilities Comparison With The General Population
January 1, 2024
MGFA 2024 Posters/Presentations
Presented at Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting
October 14 - 17, 2024
Presented at Myasthenia Gravis Foundation of America (MGFA) Scientific Session at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting
October 14 - 17, 2024
Posters
- Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
- Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Adm
- Efficacy, Safety, and Pharmacodynamics of Efgartigimod PH20 SC Across Bodyweight Quartiles A Post hoc Analysis of the ADAPT-SC+ Trial
- Exploring the Impact of Nonsteroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients With Myasthenia Gravis
- Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
- Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
- Patterns Of Efgartigimod Dosing In Clinical Practice In The United States
- Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
- Quality Of Life of Patients with Symptomatic Ocular MG Comparison with the General Population
- Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
- Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States
2025 ANEM Videos
Richard’s perspective – Living with MMN
October 29, 2025
Richard’s perspective – Living with MMN
October 29, 2025
Brenda’s Multifocal Motor Neuropathy (MMN) Story
October 29, 2025
Brenda’s Multifocal Motor Neuropathy (MMN) Story
October 29, 2025
Idiopathic Inflammatory Myopathies (Myositis), Disease Pathogenesis
October 29, 2025
Idiopathic Inflammatory Myopathies (Myositis), Disease Pathogenesis
October 29, 2025
Efgartigimod, Mechanism of Action
October 29, 2025
Efgartigimod, Mechanism of Action
October 29, 2025
AANEM 2025 Handouts
ADHERE REAL Study Flyer
January 1, 2025
ADHERE REAL Study Flyer
January 1, 2025
Empasiprubart MMN Card
January 1, 2025
Empasiprubart MMN Card
January 1, 2025
ALS clinical study card
January 1, 2025
ALS clinical study card
January 1, 2025
ALKIVIA clinical study card
January 1, 2025
ALKIVIA clinical study card
January 1, 2025
VYVGART Pregnancy study
January 1, 2025
VYVGART Pregnancy study
January 1, 2025
ADAPT OCULUS clinical study card
January 1, 2025
ADAPT OCULUS clinical study card
January 1, 2025
Immunology Innovation Program flyer
January 1, 2025
Immunology Innovation Program flyer
January 1, 2025
MMN Disease State Handout
January 1, 2025
MMN Disease State Handout
January 1, 2025
Myositis Disease State Handout
January 1, 2025
Myositis Disease State Handout
January 1, 2025
Efgartigimod Mechanism of Action Handout
January 1, 2025
Efgartigimod Mechanism of Action Handout
January 1, 2025
ADAPT Oculus Study handout
January 1, 2025
ADAPT Oculus Study handout
January 1, 2025
argenx pipeline handout
January 1, 2025
argenx pipeline handout
January 1, 2025
argenx Medical Affairs: Science of Collaboration Congress Handout
January 1, 2025
argenx Medical Affairs: Science of Collaboration Congress Handout
January 1, 2025
Empasiprubart 117 Proposed Mechanism of Action Handout
January 1, 2025
Empasiprubart 117 Proposed Mechanism of Action Handout
January 1, 2025
AANEM 2025 Posters
Safety and Efficacy Data From the Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
October 29, 2025
Safety and Efficacy Data From the Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
October 29, 2025
ADHERE+ Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
October 29, 2025
ADHERE+ Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
October 29, 2025
Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study239
October 29, 2025
Empasiprubart in Multifocal Motor Neuropathy: Exploratory Analyses of the Phase 2 ARDA Study239
October 29, 2025
Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights on Glycolipid Reactivity From the ADHERE Trial
October 29, 2025
Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights on Glycolipid Reactivity From the ADHERE Trial
October 29, 2025
Baseline Characteristics of the First 200 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study
October 29, 2025
Baseline Characteristics of the First 200 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study
October 29, 2025
Treatment Impact of Efgartigimod Ph20 Sc on I-RODS Daily Activity Assessment in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational Adhere Study
October 29, 2025
Treatment Impact of Efgartigimod Ph20 Sc on I-RODS Daily Activity Assessment in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational Adhere Study
October 29, 2025
Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy: Phase 2 Results from the ALKIVIA Study
October 29, 2025
Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy: Phase 2 Results from the ALKIVIA Study
October 29, 2025
Burden of Disease in Multifocal Motor Neuropathy: A Quantitative Survey of Patients
October 29, 2025
Burden of Disease in Multifocal Motor Neuropathy: A Quantitative Survey of Patients
October 29, 2025
Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Phase 4 Study in Progress
October 29, 2025
Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Phase 4 Study in Progress
October 29, 2025
Management of Patients with Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists
October 29, 2025
Management of Patients with Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists
October 29, 2025
Empasiprubart Versus Placebo in Chronic Inflammatory Demyelinating Polyneuropathy: EMNERGIZE Phase 3 Study Design
October 29, 2025
Empasiprubart Versus Placebo in Chronic Inflammatory Demyelinating Polyneuropathy: EMNERGIZE Phase 3 Study Design
October 29, 2025
Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION
October 29, 2025
Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION
October 29, 2025
Empasiprubart versus Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: EMVIGORATE Phase 3 Study Design
October 29, 2025
Empasiprubart versus Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: EMVIGORATE Phase 3 Study Design
October 29, 2025
Safety of Intravenous and Subcutaneous Efgartigimod Reported from Multiple Global Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
October 29, 2025
Safety of Intravenous and Subcutaneous Efgartigimod Reported from Multiple Global Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
October 29, 2025
FcRn Blocker Efgartigimod: Unique Fc Fragment Allowing IgG Reduction Without Reducing Albumin or Increasing Cholesterol
October 29, 2025
FcRn Blocker Efgartigimod: Unique Fc Fragment Allowing IgG Reduction Without Reducing Albumin or Increasing Cholesterol
October 29, 2025
Health-Related Quality of Life in Generalized Myasthenia Gravis (gMG) Patients Without Self-Reported AChR Antibodies
October 29, 2025
Health-Related Quality of Life in Generalized Myasthenia Gravis (gMG) Patients Without Self-Reported AChR Antibodies
October 29, 2025
Design of a Phase 4, Open-label, Single-group Study to Evaluate Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants with New-onset Generalized Myasthenia Gravis
October 29, 2025
Design of a Phase 4, Open-label, Single-group Study to Evaluate Clinical Outcomes of Efgartigimod PH20 SC in Adult Participants with New-onset Generalized Myasthenia Gravis
October 29, 2025
Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
October 29, 2025
Sustained Clinical Efficacy and Long-term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
October 29, 2025
Glucocorticoid Exposure and the Risk of Serious Infections in CIDP
October 29, 2025
Glucocorticoid Exposure and the Risk of Serious Infections in CIDP
October 29, 2025
Covid-19 Vaccination Response in Participants Across Clinical Trials Investigating Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20
October 29, 2025
Covid-19 Vaccination Response in Participants Across Clinical Trials Investigating Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20
October 29, 2025
Clinical Development Program for Efgartigimod in Juvenile Generalized Myasthenia Gravis
October 29, 2025
Clinical Development Program for Efgartigimod in Juvenile Generalized Myasthenia Gravis
October 29, 2025
Disability Progression and Associated Costs in Incident Early-Onset Myasthenia Gravis Patients in France: A Longitudinal Cohort Study
October 29, 2025
Disability Progression and Associated Costs in Incident Early-Onset Myasthenia Gravis Patients in France: A Longitudinal Cohort Study
October 29, 2025
Cost and Use of Medical Devices in Incident Early-onset Myasthenia Gravis Patients in France: A Longitudinal Cohort Study
October 29, 2025
Cost and Use of Medical Devices in Incident Early-onset Myasthenia Gravis Patients in France: A Longitudinal Cohort Study
October 29, 2025
Myasthenia Gravis Events in a Retrospective United States Claims Database Study
October 29, 2025
Myasthenia Gravis Events in a Retrospective United States Claims Database Study
October 29, 2025
Investigating the Pharmacodynamics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
October 29, 2025
Investigating the Pharmacodynamics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
October 29, 2025
A Real-World Retrospective Cohort Study Characterizing Patients with MMN in the United States
October 29, 2025
A Real-World Retrospective Cohort Study Characterizing Patients with MMN in the United States
October 29, 2025
Difference in oral glucocorticoid utilization based on prior myasthenia gravis treatment exposure among patients using efgartigimod
October 29, 2025
Difference in oral glucocorticoid utilization based on prior myasthenia gravis treatment exposure among patients using efgartigimod
October 29, 2025
Impact of Subcutaneous Efgartigimod PH20 on Autoimmunity Biomarkers in the ADHERE Trial: Exploratory Analyses
October 29, 2025
Impact of Subcutaneous Efgartigimod PH20 on Autoimmunity Biomarkers in the ADHERE Trial: Exploratory Analyses
October 29, 2025
Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants with Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study
October 29, 2025
Long-term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants with Generalized Myasthenia Gravis: Final Results of the ADAPT-SC+ Study
October 29, 2025
MGFA 2025 Posters/Presentations
Myasthenia Gravis Foundation of America Scientific Session at AANEM (MGFA-SS)
October 29, 2025
-
San Francisco, CA
Myasthenia Gravis Foundation of America Scientific Session at AANEM (MGFA-SS)
October 29, 2025
-
San Francisco, CA
Posters
- Assessing social media sentiment to analyze patient, caregiver and healthcare professionals experience with VYVGART and VYVGART Hytrulo for generalized Myasthenia Gravis
- Comparative Analysis of Patient Social Media Sentiment for VYVGART in gMG Compared to Treatments in Other Complex Disease Areas
- Comparative Benefits of Immunomodulatory Therapies for Generalized Myasthenia Gravis
- Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
- Diagnosis Journey, Treatment, and Management of Patients with Ocular Myasthenia Gravis: Insights from a U.S. Patient Panel
- Differences Between Patient and Provider Perceptions in Assessing Myasthenia Gravis Disease Burden and Minimal Symptom Expression: A Real-World Survey
- Disease Burden, Impact on Daily Functioning, and Psychological Well-being in Patients with Ocular Myasthenia Gravis: Insights from a U.S. Patient Panel
- Drivers of Mortality in Patients with Myasthenia Gravis in the United States National Veterans Affairs Health Care Network and Medicare Databases
- Impact of Long-Term Intravenous Efgartigimod on Quality of Life, Disease Severity, and Safety in Participants With Generalized Myasthenia Gravis During ADAPT NXT
- Evaluation of Cardiovascular Comorbidity Burden in Patients With Generalized Myasthenia Gravis Treated With Efgartigimod
- High Cardiovascular Disease Burden Among Patients With Myasthenia Gravis in the US
- Patient characteristics, dosing patterns, and outcomes associated with intravenous and subcutaneous efgartigimod among patients with generalized myasthenia gravis in clinical practice
Oral Presentations
- Results From the ADAPT Jr Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis
- Reduction in oral glucocorticoid use at 18 months following efgartigimod initiation based on a United States claims database
- Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti- Acetylcholine Receptor Antibody–Negative Generalized Myasthenia Gravis
MGFA 2026 Posters/Presentations
Myasthenia Gravis Foundation of America Scientific Session at AANEM (MGFA-SS)
September 29, 2026
-
Orlando, FL
Myasthenia Gravis Foundation of America Scientific Session at AANEM (MGFA-SS)
September 29, 2026
-
Orlando, FL
Posters
- Clinical and Molecular Differentiation of Efgartigimod in Generalized Myasthenia Gravis
- Efficacy and Safety of Efgartigimod in Participants With Generalized Myasthenia Gravis Who Lack Detectable Anti-Acetylcholine Receptor Antibodies: One-Year Results of ADAPT SERON
- Rapid, Sustained Improvements With Efgartigimod in Symptoms, Daily Life, And Patient Satisfaction in Generalized Myasthenia Gravis: Initial Results From the PREMIER Study
- Safety of Efgartigimod Treatment During Pregnancy for Patients with Generalized Myasthenia Gravis
- Association of Earlier Efgartigimod Initiation With Improved Clinical Outcomes in Myasthenia Gravis
- Comparing AChR-Ab-positive and AChR-Ab-negative Generalized Myasthenia Gravis: A Real-world MyaReg Analysis Including Antibody-defined Subtypes
- Interpreting Clinically Meaningful Improvement on the Myasthenia Gravis Impairment Index (MGII) Patient Reported Outcome (PRO) Ocular Score: Responder Analyses from a Phase 3 Clinical Trial in Ocular Myasthenia Gravis
- Psychometric Evaluation of the Myasthenia Gravis Impairment Index (MGII) Patient-Reported Outcome (PRO) Ocular score in Ocular Myasthenia Gravis: Results from a Phase III Clinical Trial in Ocular Myasthenia Gravis
AANEM 2026 Posters
Steroid tapering among patients with generalized myasthenia gravis (gMG) receiving efgartigimod: Interim results from the STRIVE-gMG chart review
September 29, 2026
Steroid tapering among patients with generalized myasthenia gravis (gMG) receiving efgartigimod: Interim results from the STRIVE-gMG chart review
September 29, 2026
Efficacy and Safety of Efgartigimod in Participants With Generalized Myasthenia Gravis Who Lack Detectable Anti-Acetylcholine Receptor Antibodies: One-Year Results of ADAPT SERON
September 29, 2026
Efficacy and Safety of Efgartigimod in Participants With Generalized Myasthenia Gravis Who Lack Detectable Anti-Acetylcholine Receptor Antibodies: One-Year Results of ADAPT SERON
September 29, 2026
Efgartigimod Is a Unique Neonatal Fc Receptor Blocker That Allows Immunoglobulin G Reduction Without Broad Inhibition of Immune Responses
September 29, 2026
Efgartigimod Is a Unique Neonatal Fc Receptor Blocker That Allows Immunoglobulin G Reduction Without Broad Inhibition of Immune Responses
September 29, 2026
Long-Term Safety and Sustained Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis During ADAPT-SC+
September 29, 2026
Long-Term Safety and Sustained Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis During ADAPT-SC+
September 29, 2026
Design of a Phase 2a Study to Evaluate the Safety, Efficacy, and Tolerability of Intravenous Empasiprubart as an Add-On Therapy to Intravenous Efgartigimod in Adult Participants With Generalized Myasthenia Gravis
September 29, 2026
Design of a Phase 2a Study to Evaluate the Safety, Efficacy, and Tolerability of Intravenous Empasiprubart as an Add-On Therapy to Intravenous Efgartigimod in Adult Participants With Generalized Myasthenia Gravis
September 29, 2026
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for gMG: Final Analysis of ADAPT NXT
September 29, 2026
Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for gMG: Final Analysis of ADAPT NXT
September 29, 2026
ADAPTED ENCORE: Results From the ADAPT JR Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis
September 29, 2026
ADAPTED ENCORE: Results From the ADAPT JR Study Investigating Intravenous Efgartigimod in Juvenile Generalized Myasthenia Gravis
September 29, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis: Interim Results of ADAPT OCULUS Part A
September 29, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis: Interim Results of ADAPT OCULUS Part A
September 29, 2026
Advancing Digital Measures of Walking With Qualitative Evidence: Findings From a Phase 1b Study in DOK7-Congenital Myasthenic Syndromes
September 29, 2026
Advancing Digital Measures of Walking With Qualitative Evidence: Findings From a Phase 1b Study in DOK7-Congenital Myasthenic Syndromes
September 29, 2026
Bridging Perspectives in Idiopathic Inflammatory Myopathies: An International Survey of Health care Specialist Practice Patterns, Treatment Goals, and Unmet Needs
September 29, 2026
Bridging Perspectives in Idiopathic Inflammatory Myopathies: An International Survey of Health care Specialist Practice Patterns, Treatment Goals, and Unmet Needs
September 29, 2026
Empasiprubart Versus Placebo (EMNERGIZE) or Immunoglobulin (EMVIGORATE) in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Study Designs
September 29, 2026
Empasiprubart Versus Placebo (EMNERGIZE) or Immunoglobulin (EMVIGORATE) in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Study Designs
September 29, 2026
Evaluation of the Effect of Empasiprubart on Nerve Morphology in Multifocal Motor Neuropathy: Study Design
September 29, 2026
Evaluation of the Effect of Empasiprubart on Nerve Morphology in Multifocal Motor Neuropathy: Study Design
September 29, 2026
Immunoglobulin-G Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Interpreting Glycolipid Reactivity From the ADHERE Trial
September 29, 2026
Immunoglobulin-G Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Interpreting Glycolipid Reactivity From the ADHERE Trial
September 29, 2026
Impact of Subcutaneous Efgartigimod PH20 on Grip Strength Assessment In Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Post Hoc Analysis of the ADHERE/ADHERE+ Study
September 29, 2026
Impact of Subcutaneous Efgartigimod PH20 on Grip Strength Assessment In Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Post Hoc Analysis of the ADHERE/ADHERE+ Study
September 29, 2026
Long-Term Impact of Subcutaneous Efgartigimod PH20 on Treatment-Naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Post Hoc Analysis of the ADHERE/ADHERE+ Trial
September 29, 2026
Long-Term Impact of Subcutaneous Efgartigimod PH20 on Treatment-Naïve Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Post Hoc Analysis of the ADHERE/ADHERE+ Trial
September 29, 2026
Long-Term Safety And Efficacy Data of Empasiprubart in Multifocal Motor Neuropathy: Phase 2 ARDA+ Study
September 29, 2026
Long-Term Safety And Efficacy Data of Empasiprubart in Multifocal Motor Neuropathy: Phase 2 ARDA+ Study
September 29, 2026
Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Active Idiopathic Inflammatory Myopathy: Results From the Phase 2 Randomized ALKIVIA and Open-Label Extension ALKIVIA+ Trials
September 29, 2026
Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Active Idiopathic Inflammatory Myopathy: Results From the Phase 2 Randomized ALKIVIA and Open-Label Extension ALKIVIA+ Trials
September 29, 2026
Neurofilament Light Chain as a Biomarker in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights From ADHERE
September 29, 2026
Neurofilament Light Chain as a Biomarker in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights From ADHERE
September 29, 2026
Pathway-Selective Complement Blockade and its Impact on Bacterial Cell Killing
September 29, 2026
Pathway-Selective Complement Blockade and its Impact on Bacterial Cell Killing
September 29, 2026
Phase 1b Study of Adimanebart in DOK7-Congenital Myasthenic Syndromes: Clinical Relevance of Digital Gait Outcomes
September 29, 2026
Phase 1b Study of Adimanebart in DOK7-Congenital Myasthenic Syndromes: Clinical Relevance of Digital Gait Outcomes
September 29, 2026
Real-World Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design
September 29, 2026
Real-World Effectiveness and Use of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE REAL Study Design
September 29, 2026
Safety of Intravenous and Subcutaneous Efgartigimod Reported From Multiple Global Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
September 29, 2026
Safety of Intravenous and Subcutaneous Efgartigimod Reported From Multiple Global Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
September 29, 2026
Subcutaneous Efgartigimod PH20 Treatment of a Patient With Autoimmune Nodopathy
September 29, 2026
Subcutaneous Efgartigimod PH20 Treatment of a Patient With Autoimmune Nodopathy
September 29, 2026
Long-Term Clinical Outcomes of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis
September 29, 2026
Long-Term Clinical Outcomes of Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: ADHERE/ADHERE+ Trial Interim Analysis
September 29, 2026
Understanding the Patient Journey in Multifocal Motor Neuropathy (MMN): Descriptive Insights From the iMMersioN Study
September 29, 2026
Understanding the Patient Journey in Multifocal Motor Neuropathy (MMN): Descriptive Insights From the iMMersioN Study
September 29, 2026
Analysis of Real-World Data Following the Use of Efgartigimod for the Treatment of Myasthenia Gravis in the Canadian Population through the MyPATH Patient Support Program
September 29, 2026
Analysis of Real-World Data Following the Use of Efgartigimod for the Treatment of Myasthenia Gravis in the Canadian Population through the MyPATH Patient Support Program
September 29, 2026
Clinical Effectiveness of Efgartigimod Among Patients With Generalized Myasthenia Gravis: Real-World Evidence From a Patient Support Program in Canada
September 29, 2026
Clinical Effectiveness of Efgartigimod Among Patients With Generalized Myasthenia Gravis: Real-World Evidence From a Patient Support Program in Canada
September 29, 2026
Patient Perspectives on Meaningful Change in the Myasthenia Gravis Impairment Index (MGII) Patient-Reported Outcome (PRO) Ocular Score: Exit Interviews from a Phase 3 Clinical Trial in Ocular Myasthenia Gravis
September 29, 2026
Patient Perspectives on Meaningful Change in the Myasthenia Gravis Impairment Index (MGII) Patient-Reported Outcome (PRO) Ocular Score: Exit Interviews from a Phase 3 Clinical Trial in Ocular Myasthenia Gravis
September 29, 2026
Real-world Characteristics and Treatment Patterns Among Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Initiating Subcutaneous Efgartigimod in the United States
September 29, 2026
Real-world Characteristics and Treatment Patterns Among Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Initiating Subcutaneous Efgartigimod in the United States
September 29, 2026
AANEM 2026 Handouts
Congenital Myasthenic Syndrome (CMS) Disease State Handout
January 1, 2026
Congenital Myasthenic Syndrome (CMS) Disease State Handout
January 1, 2026
Congenital Myasthenic Syndrome (CMS) vs congenital myopathy
January 1, 2026
Congenital Myasthenic Syndrome (CMS) vs congenital myopathy
January 1, 2026
Congenital Myasthenic Syndrome (CMS) vs myasthenia gravis
January 1, 2026
Congenital Myasthenic Syndrome (CMS) vs myasthenia gravis
January 1, 2026
Congenital Myasthenic Syndrome (CMS) vs muscular dystrophy
January 1, 2026
Congenital Myasthenic Syndrome (CMS) vs muscular dystrophy
January 1, 2026
Empasiprubart Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): emnergise & emvigorate Trial Awareness Handout
January 1, 2026
Empasiprubart Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): emnergise & emvigorate Trial Awareness Handout
January 1, 2026
argenx Pipeline Handout
January 1, 2026
argenx Pipeline Handout
January 1, 2026
Multifocal Motor Neuropathy (MMN) Disease State Education Handout
January 1, 2026
Multifocal Motor Neuropathy (MMN) Disease State Education Handout
January 1, 2026
VYVGART/VYVGART HYTRULO: generalized myasthenia gravis (gMG) and Chronic inflammatory demyelinating polyneuropathy (CIDP) Cross-Indication Safety Neurology Congress Handout
January 1, 2026
VYVGART/VYVGART HYTRULO: generalized myasthenia gravis (gMG) and Chronic inflammatory demyelinating polyneuropathy (CIDP) Cross-Indication Safety Neurology Congress Handout
January 1, 2026
Chronic inflammatory demyelinating polyneuropathy (CIDP) Compass Study Clinician Flyer
January 1, 2026
Chronic inflammatory demyelinating polyneuropathy (CIDP) Compass Study Clinician Flyer
January 1, 2026
To report SUSPECTED ADVERSE REACTIONS, contact argenx at 1-833-argx411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx.
© 2026 argenx MED-US-NON-2400036 v6 04/2026. All Rights Reserved.